The historical rank and industry rank for Y.S.P. Southeast Asia Holding Bhd's Net Margin % or its related term are showing as below:
XKLS:7178'
s Net Margin % Range Over the Past 10 Years
Min: 5.39 Med: 7.79 Max: 11.64
Current: 6.47
XKLS:7178's Net Margin % is ranked better than 53.31% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs XKLS:7178: 6.47
Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Y.S.P. Southeast Asia Holding Bhd Net Margin % Related Terms
Y.S.P. Southeast Asia Holding Bhd Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y.S.P. Southeast Asia Holding Bhd Net Margin % Chart
XKLS:7178 vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Y.S.P. Southeast Asia Holding Bhd's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y.S.P. Southeast Asia Holding Bhd Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Y.S.P. Southeast Asia Holding Bhd's Net Margin % distribution charts can be found below:
* The bar in red indicates where Y.S.P. Southeast Asia Holding Bhd's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) has a Net Margin % of 9.52% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Y.S.P. Southeast Asia Holding Bhd and its competitors. This is 22% above median its historical median of 7.79. Over the past decade, Y.S.P. Southeast Asia Holding Bhd's Net Margin % has ranged from 5.39 to 11.64. According to the industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #445 out of 953 companies in the Drug Manufacturers industry, placing it in the top 46.7%.
Is Y.S.P. Southeast Asia Holding Bhd's Net Margin % too high?
Y.S.P. Southeast Asia Holding Bhd's current Net Margin % of 9.52% is 22% above median its 10-year median of 7.79. Over the past 10 years, this metric has ranged from a low of 5.39 to a high of 11.64. The Drug Manufacturers industry median Net Margin % is 5.69. Y.S.P. Southeast Asia Holding Bhd's value of 9.52% is 67.3% above this industry median. Based on the distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #445 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Y.S.P. Southeast Asia Holding Bhd has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Y.S.P. Southeast Asia Holding Bhd's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #445 out of 953 companies for Net Margin %. This puts Y.S.P. Southeast Asia Holding Bhd in the upper half of its industry. The industry median Net Margin % is 5.69. Y.S.P. Southeast Asia Holding Bhd's value of 9.52% is 67.3% above this benchmark. Historically, Y.S.P. Southeast Asia Holding Bhd's own Net Margin % has ranged from 5.39 to 11.64 over the past decade. While the company's 10-year median is 7.79 vs. the industry median of 5.69, Y.S.P. Southeast Asia Holding Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Y.S.P. Southeast Asia Holding Bhd's current Net Margin % of 9.52% is 67.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Y.S.P. Southeast Asia Holding Bhd and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Y.S.P. Southeast Asia Holding Bhd's current Net Margin % is 9.52%, which is 22% above median its own 10-year median of 7.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Y.S.P. Southeast Asia Holding Bhd stock overvalued right now?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) is currently considered Modestly Undervalued. The stock's GF Value™ is RM2.40, compared to a current price of RM2.04 — trading 15% below its estimated fair value. The current Net Margin % is 9.52%, which is 22% above median its 10-year median of 7.79 and 67.3% above the Drug Manufacturers industry median of 5.69. Y.S.P. Southeast Asia Holding Bhd's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Y.S.P. Southeast Asia Holding Bhd (XKLS:7178), the current Net Margin % is 9.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) Overvalued in 2026?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd stock appears to be undervalued.
The current stock price of RM2.04 is trading 15% below its estimated GF Value™ of RM2.40.
GuruFocus considers Y.S.P. Southeast Asia Holding Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7178:
Net Margin %: 9.52% (22% above median its 10-year median of 7.79)
GF Value™: RM2.40 vs. price of RM2.04 (15% below fair value)
Industry Position: 67.3% above the Drug Manufacturers median (#445 of 953)
No single metric tells the full story. See the XKLS:7178 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Y.S.P. Southeast Asia Holding Bhd Business Description
Y.S.P. Southeast Asia Holding Bhd is an investment company, that engages in the pharmaceutical business, and provision of management services. The company operates through the following segments: Trading, Manufacturing, and Investment Holding. The Trading segment imports, exports, and trading in various kinds of pharmaceutical products, and traditional herbal and veterinary products. The Manufacturing segment manufactures pharmaceutical products. The Investment Holding segment focuses on investment holding activity. The firm's majority of revenue comes from the Manufacturing segment. The majority of revenue is derived from Malaysia.
82GF Score
Get the complete analysis for XKLS:7178
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7178 has been successfully added to your 
